You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
2026 › March › 20
Fresh
3 months ago
Donanemab and lecanemab have been shown to delay progression from mild to moderate Alzheimer's by up to six months but are not currently available on NHS.
page 1 of 1